GB201517859D0 - Novel compounds and therapeutic uses thereof - Google Patents

Novel compounds and therapeutic uses thereof

Info

Publication number
GB201517859D0
GB201517859D0 GBGB1517859.3A GB201517859A GB201517859D0 GB 201517859 D0 GB201517859 D0 GB 201517859D0 GB 201517859 A GB201517859 A GB 201517859A GB 201517859 D0 GB201517859 D0 GB 201517859D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
therapeutic uses
therapeutic
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1517859.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centauri Therapeutics Ltd
Original Assignee
Altermune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altermune Ltd filed Critical Altermune Ltd
Priority to GBGB1517859.3A priority Critical patent/GB201517859D0/en
Publication of GB201517859D0 publication Critical patent/GB201517859D0/en
Priority to US15/766,193 priority patent/US10953100B2/en
Priority to PCT/GB2016/053134 priority patent/WO2017060729A1/en
Priority to JP2018537732A priority patent/JP7065775B2/ja
Priority to CA3001084A priority patent/CA3001084C/en
Priority to EP16781531.5A priority patent/EP3359201A1/en
Priority to PCT/GB2016/053133 priority patent/WO2017060728A1/en
Priority to CN201680071566.0A priority patent/CN108472381B/zh
Priority to AU2016335365A priority patent/AU2016335365B2/en
Priority to NZ741118A priority patent/NZ741118B2/en
Priority to IL258511A priority patent/IL258511B/en
Priority to ZA2018/02256A priority patent/ZA201802256B/en
Priority to US17/188,532 priority patent/US20210369850A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Central Air Conditioning (AREA)
  • Air Filters, Heat-Exchange Apparatuses, And Housings Of Air-Conditioning Units (AREA)
GBGB1517859.3A 2015-10-08 2015-10-08 Novel compounds and therapeutic uses thereof Ceased GB201517859D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1517859.3A GB201517859D0 (en) 2015-10-08 2015-10-08 Novel compounds and therapeutic uses thereof
NZ741118A NZ741118B2 (en) 2016-10-07 Compounds and therapeutic uses thereof
PCT/GB2016/053133 WO2017060728A1 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof
PCT/GB2016/053134 WO2017060729A1 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof
JP2018537732A JP7065775B2 (ja) 2015-10-08 2016-10-07 化合物及びそれらの治療用途
CA3001084A CA3001084C (en) 2015-10-08 2016-10-07 Aptamer or biotin conjugates for the treatment of cancer or infectious diseases
EP16781531.5A EP3359201A1 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof
US15/766,193 US10953100B2 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof
CN201680071566.0A CN108472381B (zh) 2015-10-08 2016-10-07 化合物及其治疗用途
AU2016335365A AU2016335365B2 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof
IL258511A IL258511B (en) 2015-10-08 2018-04-05 Compounds and their medicinal uses
ZA2018/02256A ZA201802256B (en) 2015-10-08 2018-04-06 Compounds and therapeutic uses thereof
US17/188,532 US20210369850A1 (en) 2015-10-08 2021-03-01 Compounds and therapeutic uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1517859.3A GB201517859D0 (en) 2015-10-08 2015-10-08 Novel compounds and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
GB201517859D0 true GB201517859D0 (en) 2015-11-25

Family

ID=55130801

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1517859.3A Ceased GB201517859D0 (en) 2015-10-08 2015-10-08 Novel compounds and therapeutic uses thereof

Country Status (9)

Country Link
US (2) US10953100B2 (enExample)
EP (1) EP3359201A1 (enExample)
JP (1) JP7065775B2 (enExample)
CN (1) CN108472381B (enExample)
AU (1) AU2016335365B2 (enExample)
GB (1) GB201517859D0 (enExample)
IL (1) IL258511B (enExample)
WO (2) WO2017060728A1 (enExample)
ZA (1) ZA201802256B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3512544B1 (en) 2016-09-13 2020-10-28 Centauri Therapeutics Limited Peptide compounds and therapeutic uses thereof
GB201707076D0 (en) * 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201705684D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201707079D0 (en) * 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof
GB201816554D0 (en) * 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
CN111748089B (zh) * 2019-03-28 2023-07-18 成都先导药物开发股份有限公司 一种生物素标记化合物以及确定化合物结合靶标蛋白的方法
CN116535449B (zh) * 2023-03-22 2025-09-16 华东理工大学 一种糖基没食子酸类衍生物及其制备方法与在制备乳腺癌靶向诊疗材料中的应用
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
AU2003255544A1 (en) 2002-08-20 2004-03-11 Biotie Therapies Corp. Tumor specific oligosaccharide epitopes and use thereof
JP4430344B2 (ja) * 2002-09-09 2010-03-10 独立行政法人科学技術振興機構 多岐用途型リンカー化合物及びリガンド、並びにそれらの製造方法
EP1653977A2 (en) 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
CN101360728A (zh) * 2005-10-25 2009-02-04 艾吉拉医疗股份有限公司 Iap bir结构域结合化合物
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
WO2010129666A1 (en) 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
US9636419B2 (en) * 2013-10-11 2017-05-02 The Universit of Kansas Targeting multiple receptors on a cell surface for specific cell targeting
GB201411150D0 (en) * 2014-06-23 2014-08-06 Altermune Technologies Llc Novel aptamers and therapeutic uses thereof

Also Published As

Publication number Publication date
AU2016335365A1 (en) 2018-04-26
JP7065775B2 (ja) 2022-05-12
US10953100B2 (en) 2021-03-23
EP3359201A1 (en) 2018-08-15
WO2017060728A1 (en) 2017-04-13
NZ741118A (en) 2024-07-26
IL258511A (en) 2018-06-28
JP2018531287A (ja) 2018-10-25
WO2017060729A1 (en) 2017-04-13
US20210369850A1 (en) 2021-12-02
AU2016335365B2 (en) 2021-12-09
ZA201802256B (en) 2019-01-30
CN108472381A (zh) 2018-08-31
US20180280521A1 (en) 2018-10-04
CN108472381B (zh) 2023-06-06
CA3001084A1 (en) 2017-04-13
IL258511B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
IL258931A (en) Medicinal compounds and methods
GB201403093D0 (en) Therapeutic compounds and their use
SG11201706029VA (en) Anti-senescence compounds and uses thereof
GB201512365D0 (en) Novel therapy
ZA201802256B (en) Compounds and therapeutic uses thereof
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
ZA201705456B (en) Benzoxaborole compounds and uses thereof
GB201502412D0 (en) Therapeutic use
GB201608797D0 (en) Therapeutic use
IL265269B (en) New compounds and their medicinal uses
IL253459B (en) Isoergoline compounds and their uses
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
IL270460B1 (en) New compounds and their medicinal uses
GB201516068D0 (en) Novel therapy
GB201505382D0 (en) Novel therapy
GB201506786D0 (en) Therapeutic use
IL257737B (en) Medical compounds based on methanopyrrolo-pyridine-carboxylate and their synthesis
GB201705684D0 (en) Novel compounds and therapeutic uses thereof
GB201615560D0 (en) Novel compounds and therapeutic uses thereof
GB201707076D0 (en) Novel compounds and therapeutic uses thereof
GB201705682D0 (en) Novel compounds and therapeutic uses thereof
GB201705681D0 (en) Novel compounds and therapeutic uses thereof
GB201705678D0 (en) Novel compounds and therapeutic uses thereof
GB201705685D0 (en) Novel compounds and therapeutic uses thereof
GB201705683D0 (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)